July 2026

ONCOLOGY

INCREASING CLINICAL TRIAL ENROLLMENT WITH AI TOOLS

Over the past two years, Northwestern Medicine has contributed oncology expertise and a pilot environment for AI-powered products designed and developed by Vizlitics, a company building healthcare AI products. As a result of this collaboration, along with support from a NIH SBIR Phase II contract, Northwestern Medicine has implemented several of their tools.

These products use AI to curate longitudinal patient data, extract structured clinical information from unstructured records including faxes and media files, and automatically pre-screen patients for clinical trial eligibility. They’re designed to support clinical research teams and fit into existing workflows by screening over 95% of the patients before their upcoming consultation.

Structured patient data extracted for pre-screening and research spans patients screening, diagnosis, treatments, comorbidities and outcomes across complete patient’s care journey.

“Clinical trial participation remains one of the most challenging areas in oncology, driven in large part by fragmented data systems and manual workflows,” says Deva Mahalingam, MD, PhD, associate director of Clinical Research at Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Implementing this technology enables earlier identification of eligible patients, reduces operational burden on research teams, expands access to clinical trials and helps generate research-grade structured clinical data at scale.”
Deva Mahalingam, MD, PhD, Professor, of Hematology and Oncology

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like